Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: therapy combination + cancer cells + researchers  Related to the article below (Last Update: 5/5/2008)

Targeted Combination Therapy Triggers Cell Death in Mouse Models ...
Science Daily (press release) - Apr 29, 2008
Treating cancer cells with the combination of bortezomib and MD5-1 increased cell death in kidney cancer cells from 34 percent to 95 percent, compared with ...
Targeted Therapy Combination Overcomes Treatment Resistance In ...
Science Daily (press release) - Apr 15, 2008
They found that treating liver cancer cells with sorafenib and an antibody or the natural ligand that stimulates programmed cell death via the TRAIL pathway ...
Potential Viral Therapy Weapon For Difficult Cancers Is Safe And ...
Science Daily (press release) - Apr 22, 2008
"Just as important is the fact that the combination of rRp450 and CPA appears to be well tolerated, because non-cancer bearing mice treated with the therapy ...
Immunotherapy: Enlisting The Immune System To Fight Cancer
Science Daily (press release) - Apr 17, 2008
Researchers have found a promising synergy of two therapies to treat metastatic prostate cancer that is resistant to hormone therapy. In a phase I trial, ...

Economist
Cancer therapy Stemming the tumorous tide
Economist, UK - Apr 17, 2008
Indeed, many researchers think that the underlying cause of cancer is the brakes coming off the regulatory system that stops normal stem cells from ...
Multiple Studies Demonstrate The Use Of Hyperthermia Therapy In ...
Medical News Today (press release), UK - Apr 28, 2008
To explore the effects of hyperthermia therapy in the formation of NF-kB, the group treated cultured human pancreatic cancer cells with gemcitabine, ...
Major trial of cancer vaccines planned
The Daily Yomiuri, Japan - Apr 26, 2008
Researchers expect the vaccines will stimulate white blood cells, which attack cancer cells, leading to a decrease in the number of cancer cells as well as ...
Prostate Cancer Can Be Halted With Anti-inflammatory And Statin ...
Science Daily (press release) - Apr 14, 2008
Treatment at this stage involves either decreasing the production of the hormone or blocking its actions on the cancer cells. "Anti-androgen therapy slows ...
New Treatment Combination for Pancreatic Cancer May Improve Survival
Cancer Consultants, ID - Apr 29, 2008
A recent study published by the National Cancer Institute indicates that the combination of photodynamic therapy (PDT) and endoscopic retrograde ...
Double Binding Sites On Tumor Target May Provide Future ...
Science Daily (press release) - Apr 8, 2008
"These findings imply that a combination therapy using both types of EGFR drugs could be developed and tested," says Ferguson. ...
Source: Google News

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy -
N Immunology, D Discovery - Nature Medicine, 2001 - palgrave-journals.com
... The original rationale for combination therapy was to ... Teicher, BA A systems approach
to cancer therapy. ... American Association for Cancer Research 92nd Annual ...

The Hypoxic Cell A Target for Selective Cancer Therapy-Eighteenth Bruce F. Cain Memorial Award … -
JM Brown - Cancer Research, 1999 - AACR
... motivation for developing neutron beams for therapy, but the ... with advanced non-small
cell lung cancer treated in a ... cisplatin alone or with a combination of TPZ ...

… (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells -
R Rodriguez - Cancer Research, 1997 - AACR
... CN706 destroyed large LNCaP tumors (1 x 10(9) cells) and abolished ... Van Meir Use of
Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin ...

… in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III … -
RS Herbst, G Giaccone, JH Schiller, RB Natale, V … - Journal of Clinical Oncology, 2004 - jco.ascopubs.org
... when administered alone or in combination with chemotherapy ... However, sensitivity
to anti-EGFR therapy does not ... trastuzumab in metastatic breast cancer, where a ...

… ) An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy -
AE Wakeling, SP Guy, JR Woodburn, SE Ashton, BJ … - Cancer Research, 2002 - AACR
... on New Drugs in Cancer Therapy, Amsterdam, 2000 ... Determines Response of Colorectal
Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy ...

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 … -
RJ Pietras, MD Pegram, RS Finn, DA Maneval, DJ … - Oncogene, 1998 - nature.com
... Human breast and ovarian cancer cells which overexpress HER ... resumed on termination
of antibody therapy, indicating a ... were treated with a combination of antibody ...

… , in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer -
FR Khuri, J Nemunaitis, I Ganly, J Arseneau, IF … - Nature Medicine, 2000 - nature.com
... in patients with recurrent head and neck cancer, disease recurs rapidly with either
therapy alone. ... a phase II trial of a combination of intratumoral ONYX ...

Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy -
MA Shah, GK Schwartz - Clinical Cancer Research, 2001 - AACR
... An Emerging Concept in Cancer Therapy 1. ... MAS, GKS], Memorial Sloan-Kettering Cancer
Center, New ... The rationale for combination chemotherapy has centered, in the ...

Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained … -
SH Chen - Cancer Research, 1996 - AACR
... The effectiveness of combination therapy using a suicide gene ... of Immature Myeloid
Gr-1+ Cells in the Development of Antitumor Immunity Cancer Res., February 1 ...

… a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy -
D Finzi, J Blankson, JD Siliciano, JB Margolick, K … - Nat Med, 1999 - palgrave-journals.com
... 6 Partners AIDS Research Center and Infectious Disease ... Combination therapy for
HIV-1 infection can reduce plasma virus ... a latent form in resting CD4 + T cells. ...

Source: Google Scholar

Penn Researchers Identify New Combination Therapy That Promotes Cancer Cell Death
Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials. They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects. The Penn team reports their findings in the July issue of Cancer Cell.
To test the ability of the combined therapy in treating cancerous tumors, senior author Wafik S. El-Deiry, MD, PhD, and colleagues administered TRAIL, a tumor necrosis factor, and sorafenib, an inhibitor currently used to treat renal cancer, to mice with colon carcinomas. The sorafenib and TRAIL therapy reduced the size of tumors in mice with few side effects, demonstrating the potential effectiveness of the combined treatment on human colon cancers. "Cancer cells will do whatever it takes to survive in harsh environments," explains El-Deiry, Professor of Medicine, Genetics, and Pharmacology. To kill hearty cancer cells, El-Deiry and other scientists are working on ways to alter them so they become more susceptible to cell death.

In ongoing clinical trials, doctors are giving cancer patients extra doses of TRAIL (TNF-a-related apoptosis-inducing ligand), a molecule naturally produced by the body's immune system that promotes cell death, to help kill off cancer cells. While TRAIL-based therapy is promising, over 50 percent of all cancer cells show resistance to TRAIL. To create a more potent form of targeted cancer therapy, El-Deiry's research team began searching for ways to reverse TRAIL resistance in cancer cells.

Recently, El-Deiry's research group found that TRAIL-resistant cells avoid death by producing "survival" proteins called cIAP2 and Mcl-1. The oncogene c-Myc in part hampers a cancer cell's survival strategy by blocking the function of an intermediate protein that oversees cIAP2 and Mcl-1 production. Without these survival proteins, cancer cells are unable to resist the death initiated by TRAIL.

In search of drugs that perform a similar cancer-cell death function to c-Myc, El-Deiry's lab turned to sorafenib, which is also being considered for the treatment of a variety of cancers. Like c-Myc, the researchers found that sorafenib blocked the intermediate and survival proteins when combined with TRAIL, causing TRAIL-resistant colon and lung cancer cell lines to die.

"Our findings are exciting because TRAIL in combination with sorafenib appears to be much less toxic than current chemotherapy drugs," explains El-Deiry. "Plus, sorafenib is already available in a pill form."

While enthusiastic about his recent findings, El-Deiry notes sorafenib may be working to increase cell sensitivity to TRAIL through more biochemical pathways than the intermediate alone.

"The ability of sorafenib to work through multiple pathways may be beneficial to cancer treatments because cancer may be altering multiple targets," says El-Deiry.

In the future, El-Deiry plans to explore additional pathways sorafenib may be working through to increase TRAIL sensitivity and to compare the effectiveness of other drugs.

"In addition to proposing a combination therapy that's rational, non-toxic, and effective in preclinical trials, our findings open up new avenues of molecular exploration for designing targeted anti-cancer therapies," said El-Deiry.

Co-authors include M. Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P. Plastaras, Wenge Wang, Zhaoyu Jin, Yingqiu Y. Liu, David T. Dicker, and Keith T. Flaherty from Penn; Charles D. Smith from Pennsylvania State University; Jianhua Ling and Paul J. Chiao from the University of Texas MD Anderson Cancer Center.
The National Cancer Institute and the Littlefield-AACR award provided funding for this work.

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

http://www.uphs.upenn.edu
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.